WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 206061
Description: CB10-277 is a synthetic derivative of dimethylphenyl-triazene related to dacarbazine, with antineoplastic properties. Related to the agent dacarbazine, CB10-277 is converted in vivo to a monomethyl triazene form that alkylates DNA, resulting in inhibition of DNA replication and repair; in addition, this agent may act as a purine analogue, resulting in inhibition of DNA synthesis, and may interact with protein sulfhydryl groups.
MedKoo Cat#: 206061
Chemical Formula: C9H11N3O2
Exact Mass: 193.08513
Molecular Weight: 193.2
Elemental Analysis: C, 55.95; H, 5.74; N, 21.75; O, 16.56
CB10-277 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to email@example.com to inquire quote.
Synonym: CB10277; CB10-277; CB10 277; 1pcarboxy33dimethylphenyltriazine.
IUPAC/Chemical Name: (E)-4-(3,3-dimethyltriaz-1-en-1-yl)benzoic acid
InChi Key: GUAZPUYTLMUTMA-ZHACJKMWSA-N
InChi Code: InChI=1S/C9H11N3O2/c1-12(2)11-10-8-5-3-7(4-6-8)9(13)14/h3-6H,1-2H3,(H,13,14)/b11-10+
SMILES Code: O=C(O)C1=CC=C(/N=N/N(C)C)C=C1
The following data is based on the product molecular weight 193.2 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Bleehen NM, Calvert AH, Lee SM, Harper P, Kaye SB, Judson I, Brampton M. A Cancer Research Campaign (CRC) phase II trial of CB10-277 given by 24 hour infusion for malignant melanoma. Br J Cancer. 1994 Oct;70(4):775-7. PubMed PMID: 7917939; PubMed Central PMCID: PMC2033397.
2: Lee SM, O'Connor PJ, Thatcher N, Crowther D, Margison GP, Cooper DP. Relationships between the formation of O6-methyldeoxyguanosine by 1-p-carboxyl-3,3-dimethylphenyltriazene in DNA and O6-alkylguanine-DNA alkyltransferase in human peripheral leukocytes. Cancer Res. 1994 Aug 1;54(15):4072-6. PubMed PMID: 8033139.
3: Foster BJ, Newell DR, Gumbrell LA, Jenns KE, Calvert AH. Phase I trial with pharmacokinetics of CB10-277 given by 24 hours continuous infusion. Br J Cancer. 1993 Feb;67(2):369-73. PubMed PMID: 8431368; PubMed Central PMCID: PMC1968159.
4: Foster BJ, Newell DR, Carmichael J, Harris AL, Gumbrell LA, Jones M, Goodard PM, Calvert AH. Preclinical, phase I and pharmacokinetic studies with the dimethyl phenyltriazene CB10-277. Br J Cancer. 1993 Feb;67(2):362-8. PubMed PMID: 8431367; PubMed Central PMCID: PMC1968184.
5: Lee SM, Thatcher N, Crowther D, Margison GP. In vivo depletion of O6-alkylguanine-DNA-alkyltransferase in lymphocytes and melanoma of patients treated with CB 10-277, a new DTIC analogue. Cancer Chemother Pharmacol. 1992;31(3):240-6. PubMed PMID: 1464162.